Daprodustat - GlaxoSmithKline

Drug Profile

Daprodustat - GlaxoSmithKline

Alternative Names: 1278863; GSK-1278863; GSK-1278863A

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antianaemics; Pyrimidines; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Phase II Perioperative ischaemia
  • Phase I Diabetic foot ulcer; Tendon injuries
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 10 Apr 2018 GlaxoSmithKline plans a phase I trial for Anaemia (In adults, In volunteers) in April 2018 (NCT03493386)
  • 12 Mar 2018 GlaxoSmithKline plans a phase II trial for Anaemia (Treatment-experienced) in May 2018 (NCT03457701)
  • 05 Mar 2018 Phase-III clinical trials in Anaemia (In non-dialysis patients with chronic kidney disease) in United Kingdom and South Korea (PO) after March 2018 (NCT03409107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top